Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
Carole B. Miller(Saint Agnes Hospital), Nelson J. Chao(Duke University), María Cecilia Dignani, Joseph P. McGuirk(University of Kansas Medical Center), Steven Fruchtman(Icahn School of Medicine at Mount Sinai), Peter A. McSweeney(Mesoblast (United States)), E. Anaissie(The University of Texas MD Anderson Cancer Center), Hans-G. Klingemann(Rush University Medical Center), Edmund K. Waller(Emory University), Pablo J. Cagnoni(University of Colorado Hospital), P. Fleck(Durham University)
Cited by 28
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k